Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|1|29-39

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.1, 2015-07, pp. : 29-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series

By  

Current Urology, Vol. 9, Iss. 2, 2016-05 ,pp. : 93-103

Karger

Access to resources Recommend Favorite

Intermediate-Risk Group in Patients with Transitional Cell Carcinoma of the Bladder: Prediction of High-Risk Patients in This Heterogeneous Group

By  

Urologia Internationalis, Vol. 83, Iss. 3, 2009-10 ,pp. : 295-299

Karger

Access to resources Recommend Favorite

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

By Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 951-960

Informa Healthcare

Access to resources Recommend Favorite

Is clinical stage T2c prostate cancer an intermediate‐ or high‐risk disease?

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1414-1421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association between type 2 diabetes, curative treatment and survival in men with intermediate‐ and high‐risk localized prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 209-216

John Wiley & Sons Inc

Access to resources Recommend Favorite